Chimney Stenting for Coronary Occlusion During TAVR: Insights From the Chimney Registry.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
23 03 2020
Historique:
received: 04 11 2019
revised: 21 01 2020
accepted: 23 01 2020
entrez: 21 3 2020
pubmed: 21 3 2020
medline: 21 10 2020
Statut: ppublish

Résumé

The aim of this study was to determine the safety and efficacy of chimney stenting, a bailout technique to treat coronary artery occlusion (CAO). CAO during transcatheter aortic valve replacement (TAVR) is a rare but often fatal complication. In the international Chimney Registry, patient and procedural characteristics and data on outcomes are retrospectively collected from patients who underwent chimney stenting during TAVR. To date, 16 centers have contributed 60 cases among 12,800 TAVR procedures (0.5%). Chimney stenting was performed for 2 reasons: 1) due to the development of an established CAO (n = 25 [41.6%]); or 2) due to an impending CAO (n = 35 [58.3%]). The majority of cases (92.9%) had 1 or more classical risk factors for CAO. Upfront coronary protection was performed in 44 patients (73.3%). Procedural and in-hospital mortality occurred in 1 and 2 patients, respectively. Myocardial infarction (52.0% vs. 0.0%; p < 0.01), cardiogenic shock (52.0% vs. 2.9%; p < 0.01), and resuscitation (44.0% vs. 2.9%; p < 0.01) all occurred more frequently in patients with established CAO compared with those with impending CAO. The absence of upfront coronary protection was the sole independent risk factor for the combined endpoint of death, cardiogenic shock, or myocardial infarction. During a median follow-up time of 612 days (interquartile range: 405 to 842 days), 2 cases of stent failure were reported (1 in-stent restenosis, 1 possible late stent thrombosis) after 157 and 374 days. Chimney stenting appears to be an acceptable bailout technique for CAO, with higher event rates among those with established CAO and among those without upfront coronary protection.

Sections du résumé

OBJECTIVES
The aim of this study was to determine the safety and efficacy of chimney stenting, a bailout technique to treat coronary artery occlusion (CAO).
BACKGROUND
CAO during transcatheter aortic valve replacement (TAVR) is a rare but often fatal complication.
METHODS
In the international Chimney Registry, patient and procedural characteristics and data on outcomes are retrospectively collected from patients who underwent chimney stenting during TAVR.
RESULTS
To date, 16 centers have contributed 60 cases among 12,800 TAVR procedures (0.5%). Chimney stenting was performed for 2 reasons: 1) due to the development of an established CAO (n = 25 [41.6%]); or 2) due to an impending CAO (n = 35 [58.3%]). The majority of cases (92.9%) had 1 or more classical risk factors for CAO. Upfront coronary protection was performed in 44 patients (73.3%). Procedural and in-hospital mortality occurred in 1 and 2 patients, respectively. Myocardial infarction (52.0% vs. 0.0%; p < 0.01), cardiogenic shock (52.0% vs. 2.9%; p < 0.01), and resuscitation (44.0% vs. 2.9%; p < 0.01) all occurred more frequently in patients with established CAO compared with those with impending CAO. The absence of upfront coronary protection was the sole independent risk factor for the combined endpoint of death, cardiogenic shock, or myocardial infarction. During a median follow-up time of 612 days (interquartile range: 405 to 842 days), 2 cases of stent failure were reported (1 in-stent restenosis, 1 possible late stent thrombosis) after 157 and 374 days.
CONCLUSIONS
Chimney stenting appears to be an acceptable bailout technique for CAO, with higher event rates among those with established CAO and among those without upfront coronary protection.

Identifiants

pubmed: 32192695
pii: S1936-8798(20)30408-8
doi: 10.1016/j.jcin.2020.01.227
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

751-761

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Federico Mercanti (F)

University Hospital and SAOLTA University Health Care Group, Galway, Ireland.

Liesbeth Rosseel (L)

University Hospital and SAOLTA University Health Care Group, Galway, Ireland.

Antoinette Neylon (A)

University Hospital and SAOLTA University Health Care Group, Galway, Ireland.

Rodrigo Bagur (R)

Division of Cardiology, London Health Sciences Centre, School of Medicine & Dentistry, Western University, London, Ontario, Canada.

Jan-Malte Sinning (JM)

Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Bonn, Germany.

Georg Nickenig (G)

Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Bonn, Germany.

Eberhard Grube (E)

Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Bonn, Germany.

David Hildick-Smith (D)

Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom.

Davide Tavano (D)

IRCCS Multimedica, Sesto San Giovanni, Milan, Italy.

Alexander Wolf (A)

Department of Interventional Cardiology, Elisabeth Hospital Essen, Essen, Germany.

Giuseppe Colonna (G)

Department of Cardiology, Vito Fazzi Hospital, Lecce, Italy.

Azeem Latib (A)

Unit of Cardiovascular Interventions, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Satoru Mitomo (S)

Unit of Cardiovascular Interventions, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Anna Sonia Petronio (AS)

Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Marco Angelillis (M)

Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Didier Tchétché (D)

Clinique Pasteur, Groupe Cardiovasculaire Interventionel, Toulouse, France.

Chiara De Biase (C)

Clinique Pasteur, Groupe Cardiovasculaire Interventionel, Toulouse, France.

Marianna Adamo (M)

Cardiac Catheterization Laboratory, Cardiothoracic Department, Spedali Civili of Brescia, Brescia, Italy.

Mohammed Nejjari (M)

Hemodynamic Department, Centre Cardiologique du Nord, Saint Denis, France.

Franck Digne (F)

Hemodynamic Department, Centre Cardiologique du Nord, Saint Denis, France.

Ulrich Schäfer (U)

Department of General and Interventional Cardiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Nicolas Amabile (N)

Department of Cardiology, Institut Mutualiste Montsouris, Paris, France.

Guy Achkouty (G)

Department of Cardiology, Institut Mutualiste Montsouris, Paris, France.

Raj R Makkar (RR)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Sung-Han Yoon (SH)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Ariel Finkelstein (A)

Tel Aviv Medical Center and Tel Aviv University, Tel Aviv, Israel.

Danny Dvir (D)

Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, Washington.

Tara Jones (T)

Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, Washington.

Bernard Chevalier (B)

Institut Cardiovasculaire de Paris, Massy, France.

Thierry Lefevre (T)

Institut Cardiovasculaire de Paris, Massy, France.

Nicolo Piazza (N)

McGill University Health Centre, Montreal, Quebec, Canada.

Darren Mylotte (D)

University Hospital and SAOLTA University Health Care Group, Galway, Ireland; National University of Ireland, Galway, Ireland. Electronic address: darrenmylotte@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH